Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Questex Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Questex Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Opsumit
Financials
Remicade and Xarelto woes haven't stopped J&J hiking forecast
Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.
Arlene Weintraub
Apr 17, 2018 12:19pm
Special Report—The top 10 cardiovascular drugs in the world
Aug 28, 2017 7:00am
Actelion's Opsumit fails key study as J&J megadeal nears
Jan 23, 2017 9:13am
'Audacious' CVS drops key meds from Sanofi, Novartis and more
Aug 3, 2016 6:22am
Can Adempas meet Bayer's growth expectations after a canceled trial?
May 17, 2016 7:36am
